21 "Urinary Bladder" clinical trials found.
-
A Phase 3 Randomized Open-Label Three Arm Study of PF-06801591 in Combination with BCG (Induction With or Without Maintenance) Versus BCG (Induction and Maintenance) in Participants with HR BCG-Na ve NMIBC (B8011006)
The purpose of the study is to determine the safety and efficacy of PF-06801591 (an anti-PD-1 antibody) combined with Bacillus Calmette- Guerin (BCG) in patients ... -
A PHASE 1B OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER OR METASTATIC NON-S ALL CELL LUNG CANCER
If you have been diagnosed with locally advanced or metastatic (the spread of) melanoma, locally advanced or metastatic (the spread of) urothelial bladder cancer or ...
-
A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)
The purpose of the study is to look at safety and efficacy of study drug ABBV-151 alone and in combination with study drug ABBV-181. We ... -
An open-label randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
The purpose of the study is to evaluate the combination of enfortumab vedotin + pembrolizumab, with or without platinum-containing chemotherapy, versus standard of care gemcitabine + platinum-containing ... -
A dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with pembrolizumab and/or chemotherapy for treatment of patients with locally advanced or metastatic urothelial cancer (SGN22E-002)
The purpose of this study to find out how enfortumab vedotin, when given together with pembrolizumab, cisplatin, carboplatin, or gemcitabine, affects patients with metastatic urothelial ... -
First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
The purpose of the study is to determine the safety of GEN1046 in patients with malignant solid tumors. GEN1046 is investigational drug in this study ... -
A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors
The purpose of the study is to evaluate the safety and tolerability of the study drug CPI-0209 as monotherapy and in combination with irinotecan in ... -
Phase 1 Open-Label Multicenter Dose Escalation Study of mRNA-2752 a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L IL-23 and IL-36? for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade
The purpose of the study is to evaluate the anti-tumor activity of ITu injections of mRNA-2752 alone and in combination with intravenously administered durvalumab in ... -
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb 22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)
The purpose of the study is to assess the safety and tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab. XmAb®22841 is a ... -
A Phase 1 Study of TJ011133 Administered Alone or in Combination with Pembrolizumab or Rituximab in Subjects with Relapsed/Refractory Advanced Solid Tumors and Lymphoma
The purpose of this study is to test the safety of a study drug called TJ011133 alone, and to test the safety of TJ011133 in ...